NCT01751308 - Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

February 29, 2016

Conditions

Malignant Solid Tumor - Malignant Nervous System Neoplasm

Interventions

DRUG

Cabazitaxel (XRP6258)

Pharmaceutical form: Injection Route of administration: Intravenous

Trial Locations (13)

Investigational Site Number 840003, New York

Investigational Site Number 840011, Washington D.C.

Investigational Site Number 840010, Baltimore

Investigational Site Number 840005, Orlando

Investigational Site Number 840012, Chicago

Investigational Site Number 840006, Houston

Investigational Site Number 840007, Aurora

Investigational Site Number 840009, Phoenix

Investigational Site Number 840013, Los Angeles

Investigational Site Number 840008, Seattle

Investigational Site Number 840014, Palo Alto

Investigational Site Number 840002, Boston

Investigational Site Number 124001, Toronto